Home » Lynx Adds Two Patents to Genomics IP Portfolio

Lynx Adds Two Patents to Genomics IP Portfolio

Jan 27, 2000
Premium

H

AYWARD, Calif.--Lynx Therapeutics was recently issued a patent broadly covering its use of encoded adaptors in its Massively Parallel Signature Sequencing technology. The company has also acquired an exclusive worldwide license to a molecular tagging technology invented by George Church and Stephen Kieffer-Higgins at Harvard Medical School.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

What's Popular?

In Informatics

  1. Signature Science Wins $2.9M IARPA Contract for Biological Threat Detection Computational Tools

  2. Hearst Invests $75M in M2Gen

  3. Verge Genomics Forms ALS Research Collaboration

  4. Researchers Identify SNP Set, Develop QR Code to Distinguish Genome Samples

  5. Optalysys Readies Optical Sequencing Alignment for Market

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.